CP 55,940

Name	CP 55,940
Supplier	R&D Systems
Catalog	0949
Prices	$245.00, $1,005.00
Sizes	10 mg, 50 mg
Cas Number	83002-04-4
Chemical Name	(-)-cis-3-[2-Hydroxy-4-(1,1-dimethylheptyl)phenyl]-trans-4-(3-hydroxypropyl)cyclohexanol
Formula	C24H40O3
Molecular Weight	376.58
Purity	>98%
Supplier Page	Shop

Product References

(4-(Bis(4-fluorophenyl)methyl)piperazin-1-yl)(cyclohexyl)methanone hydrochloride - (4-(Bis(4-fluorophenyl)methyl)piperazin-1-yl)(cyclohexyl)methanone hydrochloride

Mahmoud MM, Olszewska T, Liu H, Shore DM, Hurst DP, Reggio PH, Lu D, Kendall DA. Mol Pharmacol. 2015 Feb;87(2):197-206.

Preclinical evaluation of SMM-189, a cannabinoid receptor 2-specific inverse - Preclinical evaluation of SMM-189, a cannabinoid receptor 2-specific inverse

Presley C, Abidi A, Suryawanshi S, Mustafa S, Meibohm B, Moore BM. Pharmacol Res Perspect. 2015 Aug;3(4):e00159.

Increasing levels of the endocannabinoid 2-AG is neuroprotective in the - Increasing levels of the endocannabinoid 2-AG is neuroprotective in the

Mounsey RB, Mustafa S, Robinson L, Ross RA, Riedel G, Pertwee RG, Teismann P. Exp Neurol. 2015 Nov;273:36-44.

Flavanones from Miconia prasina. - Flavanones from Miconia prasina.

Tarawneh AH, Leon F, Ibrahim MA, Pettaway S, McCurdy CR, Cutler SJ. Phytochem Lett. 2014 Feb;7:130-132.

Potential upstream regulators of cannabinoid receptor 1 signaling in prostate - Potential upstream regulators of cannabinoid receptor 1 signaling in prostate

Haggstrom J, Cipriano M, Forshell LP, Persson E, Hammarsten P, Stella N, Fowler CJ. Prostate. 2014 Aug;74(11):1107-17.

The cannabinoid agonist HU-210: pseudo-irreversible discriminative stimulus - The cannabinoid agonist HU-210: pseudo-irreversible discriminative stimulus

Hruba L, McMahon LR. Eur J Pharmacol. 2014 Mar 15;727:35-42.

Prefrontal deficits in a murine model overexpressing the down syndrome candidate - Prefrontal deficits in a murine model overexpressing the down syndrome candidate

Thomazeau A, Lassalle O, Iafrati J, Souchet B, Guedj F, Janel N, Chavis P, Delabar J, Manzoni OJ. J Neurosci. 2014 Jan 22;34(4):1138-47.

CB(1) receptor allosteric modulators display both agonist and signaling pathway - CB(1) receptor allosteric modulators display both agonist and signaling pathway

Baillie GL, Horswill JG, Anavi-Goffer S, Reggio PH, Bolognini D, Abood ME, McAllister S, Strange PG, Stephens GJ, Pertwee RG, Ross RA. Mol Pharmacol. 2013 Feb;83(2):322-38.

Long-term CB(1) receptor blockade enhances vulnerability to anxiogenic-like - Long-term CB(1) receptor blockade enhances vulnerability to anxiogenic-like

Tambaro S, Tomasi ML, Bortolato M. Neuropharmacology. 2013 Jul;70:268-77.

CB1 and CB2 receptors are novel molecular targets for Tamoxifen and - CB1 and CB2 receptors are novel molecular targets for Tamoxifen and

Prather PL, FrancisDevaraj F, Dates CR, Greer AK, Bratton SM, Ford BM, Franks LN, Radominska-Pandya A. Biochem Biophys Res Commun. 2013 Nov 15;441(2):339-43. doi: